<DOC>
	<DOCNO>NCT00296062</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , capecitabine , irinotecan , oxaliplatin , work different way stop growth tumor cell , either kill cell stop divide . Giving one drug ( combination chemotherapy ) may kill tumor cell . Monoclonal antibody , bevacizumab , block tumor growth different way . Some find tumor cell kill carry tumor-killing substance . Others interfere ability tumor cell grow spread . Bevacizumab may also block blood flow tumor . Giving combination chemotherapy together bevacizumab may kill tumor cell . PURPOSE : This phase I/II trial study side effect best dose capecitabine give together irinotecan oxaliplatin without bevacizumab see well work treat patient metastatic locally advanced colorectal cancer solid tumor remove surgery .</brief_summary>
	<brief_title>Dose Dense Therapy Bevacizumab Solid Tumors Colorectal Cancer</brief_title>
	<detailed_description>The study originally intend Phase I/Phase II terminate early toxicity treatment therefore never move Phase II portion study . OBJECTIVES : - Determine maximum tolerate dose ( MTD ) dose-limiting toxicity dose-dense dose-intense capecitabine combination alternate full-dose irinotecan hydrochloride oxaliplatin patient metastatic locally advanced unresectable solid tumor . ( phase I ) - Characterize safety MTD patient ≥ 65 year age treat regimen . ( phase I ) - Characterize pharmacokinetics regimen patient ≥ 65 year age . ( phase I ) - Characterize functional status patient ≥ 65 year age baseline study treatment , term performance status , independence activity , comorbidities , risk malnutrition , underlie depression . ( phase I ) - Characterize neurological status patient , term muscle strength sensation , baseline study treatment . ( phase I ) - Determine clinical antitumor response patient treat regimen . ( phase I ) - Determine whether addition bevacizumab dose-intense capecitabine combination alternate full-dose irinotecan hydrochloride oxaliplatin first-line treatment lead improve response rate patient metastatic colorectal cancer compare publish result fluoropyrimidine/oxaliplatin , fluoropyrimidine/irinotecan/bevacizumab , fluoropyrimidine/irinotecan regimen . ( phase II ) - Determine toxicity bevacizumab combination regimen patient metastatic colorectal cancer . ( phase II ) OUTLINE : This multicenter , phase I dose-escalation study capecitabine follow phase II study . - Phase I ( solid tumor patient ) : Patients receive oral capecitabine twice daily day 1-7 15-21 . Patients also receive irinotecan hydrochloride IV 90 minute day 1 15 course 1 subsequent odd-numbered course oxaliplatin IV 2 hour day 1 15 course 2 subsequent even-numbered course . Courses repeat every 28 day absence disease progression unacceptable toxicity Cohorts 3-6 patient receive escalate dos capecitabine ( odd- even-numbered course ) maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient ( least 1 patient &lt; 65 year age ) experience dose-limiting toxicity . At least 6 patient treated MTD . - Phase II ( colorectal cancer patient ) : Patients receive capecitabine ( MTD determine phase I ) combination irinotecan hydrochloride ( odd-numbered course ) oxaliplatin ( even-numbered course ) phase I . Patients also receive bevacizumab IV 30-90 minute day 1 15 course . After completion study treatment , patient follow periodically . PROJECTED ACCRUAL : A total 50 patient accrue study .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Phase I : Histologically cytologically confirm solid tumor Metastatic OR locally advance unresectable disease No curative therapy exist Measurable evaluable disease Measurable disease define ≥ 1 lesion accurately measure ≥ 1 dimension ≥ 20 mm conventional technique OR ≥ 10 mm spiral CT scan No known brain metastasis Phase II : Histologically cytologically confirm colorectal cancer Metastatic OR locally advance unresectable disease Measurable disease ( defined phase I ) No tumor involve major blood vessel No evidence CNS disease , include primary brain tumor brain metastasis PATIENT CHARACTERISTICS : Karnofsky performance status 70100 % Life expectancy ≥ 12 week Absolute neutrophil count ( ANC ) ≥ 1,500/mm^3 ANC &lt; 1,500/mm^3 allow , opinion investigator , represent ethnic racial variation normal Platelet count ≥ 100,000/mm^3 Hemoglobin &gt; 10.0 g/dL Bilirubin ≤ 1.5 mg/dL AST/ALT ≤ 2 time upper limit normal ( ULN ) Creatinine ≤ 1.5 mg/dL OR creatinine clearance ≥ 60 mL/min Urine protein : creatinine ratio &lt; 1.0 OR protein &lt; 1 g 24hour urine collection ( phase II ) PT/INR ≤ 1.5 unless fulldose anticoagulant ( phase II ) Not pregnant nursing Negative pregnancy test Fertile female patient must use effective doublebarrier contraception 28 day ( phase I ) 3 month ( phase II ) completion study treatment Fertile male patient must use effective contraception 6 month completion study treatment No history allergic reaction attribute compound similar chemical biologic composition capecitabine , irinotecan hydrochloride , oxaliplatin , bevacizumab No uncontrolled illness include , limited , follow : Ongoing active infection Symptomatic congestive heart failure Unstable angina pectoris Cardiac arrhythmia Psychiatric illness social situation would preclude study compliance No cardiac ischemia within past 6 month ( phase I ) No New York Heart Association class IIIV congestive heart failure symptomatic arrhythmia ( phase II ) No arterial thrombotic event within past 6 month include , limited , follow ( phase II ) : Transient ischemic attack Cerebrovascular accident Unstable angina angina require surgical medical intervention Myocardial infarction No clinically significant peripheral vascular disease ( phase II ) No history hypertension unless well control ( &lt; 150/90 mm Hg ) antihypertensive regimen ( phase II ) No evidence bleed diathesis coagulopathy ( phase II ) No gastrointestinal ( GI ) perforation , abdominal fistula , intraabdominal abscess within past 30 day ( phase II ) No significant history bleed event ( phase II ) Patients history significant bleeding episode ( e.g. , hemoptysis upper low GI bleeding ) within past 6 month eligible unless source bleeding resect No significant traumatic injury within past 28 day ( phase II ) No serious nonhealing wound , ulcer , bone fracture ( phase II ) No peripheral neuropathy &gt; grade 1 PRIOR CONCURRENT THERAPY : At least 3 week since prior chemotherapy ( 6 week nitrosoureas ) recover ( phase I ) At least 2 week since prior immunotherapy biologic therapy recover ( phase I ) No prior treatment advance metastatic colorectal cancer ( phase II ) More 12 month since prior adjuvant chemotherapy and/or biologic therapy ( e.g. , bevacizumab cetuximab ) recover ( phase II ) At least 4 week since prior radiotherapy recover No prior radiotherapy site measurable disease unless measurable disease progression within radiation port completion radiotherapy No prior radiotherapy ≥ 20 % bone marrow More 28 day since prior major surgical procedure* open biopsy recover ( phase II ) More 14 day since prior minor surgery* recover ( phase II ) Concurrent fulldose anticoagulation ( e.g. , warfarin ) allow provide follow criterion meet ( phase II ) : Patient inrange INR ( 2 3 ) stable dose oral anticoagulant stable dose low molecular weight heparin No active bleed pathological condition carry high risk bleeding ( e.g. , known varix ) No concurrent combination antiretroviral therapy HIVpositive patient No concurrent investigational agent No concurrent sargramostim ( GMCSF ) NOTE : *Insertion vascular device consider major minor surgery</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2012</verification_date>
	<keyword>unspecified adult solid tumor , protocol specific</keyword>
	<keyword>stage III colon cancer</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage III rectal cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
</DOC>